NasdaqGS:ALLOBiotechs
Why Allogene Therapeutics (ALLO) Is Up 16.8% After Early ALPHA3 MRD Clearance Data And What's Next
In April 2026, Natera highlighted interim futility analysis from Allogene Therapeutics’ registrational ALPHA3 trial, where its off‑the‑shelf anti‑CD19 CAR T candidate cema‑cel achieved molecular residual disease clearance in a majority of treated large B‑cell lymphoma patients and showed deep reductions in plasma ctDNA compared with observation alone.
Because ALPHA3 is the first MRD‑guided randomized trial in this lymphoma setting, these early data not only support cema‑cel’s potential role...